Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation

Neuro-Oncology

Volumn 16, Issue 12, 2014, Pages 1607-1617

  Jha, Prerana ^a   Patric, Irene Rosita Pia ^b   Shukla, Sudhanshu ^b   Pathak, Pankaj ^a   Pal, Jagriti ^b   Sharma, Vikas ^a   Thinagararanjan, Sivaarumugam ^b   Santosh, Vani ^a   Suri, Vaishali ^a,c   Sharma, Mehar Chand ^a   Arivazhagan, Arimappamagan ^c   Suri, Ashish ^a   Gupta, Deepak ^a   Somasundaram, Kumaravel ^b   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

G CIMP; H3F3A; IDH1; Methylation; Pediatric GBM; Reactive oxygen species (ROS)

Indexed keywords

CYTOSINE; GUANINE; H3 HISTONE FAMILY 3A; HISTONE H3; PHOSPHATE; REACTIVE OXYGEN METABOLITE; SEMAPHORIN 3F; UNCLASSIFIED DRUG; HISTONE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGE; ARTICLE; C9ORF45 GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CCDC8 GENE; CELL FATE; CHILD; CHILDHOOD CANCER; CKMT2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CPG ISLAND; FEMALE; FLJ38725 GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE ONTOLOGY; GENETIC ASSOCIATION; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; IDH1 GENE; KLF11 GENE; LOC222171 GENE; MALE; NERVE CELL DIFFERENTIATION; PROTEIN EXPRESSION; RASSF1 GENE; SEMA3F GENE; TTC12 GENE; VALIDATION STUDY; WWTR1 GENE; BRAIN TUMOR; DNA METHYLATION; GENETICS; METABOLISM; MUTATION; PRESCHOOL CHILD; TUMOR CELL LINE;

ADULT; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; REACTIVE OXYGEN SPECIES;

EID: 84919920437     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou113     Document Type: Article

References (47)

1. Kaatsch P, Kaletsch U, Spix C, et al. Annual Report 1998 German Childhood Cancer Resigtry. Mainz: Lindner; 1999.
2. Packer RJ. Primary central nervous system tumors in children. Curr Treat Options Neurol. 1999;1(5):395-408.
3. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197-206.
4. Wong KK, Tsang YT, Chang YM, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006;66(23):11172-11178.
5. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196-1208.
6. Haque T, Faury D, Albrecht S, et al. Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. Clin Cancer Res. 2007;13(21):6284-6292.
7. Suri V, Das P, Pathak P, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. [published correction appears in Neuro Oncol. 2009;11:972]. Neuro Oncol. 2009;11(3):274-280.
8. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061-3068.
9. Jha P, Suri V, Singh G, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol. 2011;20(4):225-232.
10. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061.
11. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
12. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma [published correction appears in Nature. 2012;484:130]. Nature. 2012;482(7384):226-231.
13. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251-253.
14. Weller M, Stupp R, Reifenberger G, et al. MGMTpromoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39-51.
15. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery. 2010;67(6):1681-1691.
16. Suri V, Jha P, Sharma MC, et al. O6-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status. Neurol India. 2011;59(2):229-235.
17. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
18. Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-kB nexus. Cancer Res. 2013;73(22):6563-6573.
19. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-437.
20. Kleihues P, Louis DN, Wiestler OD, et al. WHO grading of tumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC; 2007:10-49.
21. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009;4(1):44-57.
22. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
23. Lázcoz P, Muñoz J, Nistal M, et al. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer. 2006;6:254.
24. Wattanawaraporn R, Singhsilarak T, Nuchprayoon I, et al. Hypermethylation of TTC12 gene in acute lymphoblastic leukemia. Leukemia. 2007;21(11):2370-2373.
25. Dai C, Tang Y, Jung SY, et al. Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc Natl Acad Sci U S A. 2011;108(47):18937-18942.
26. Muñoz J, Inda MM, Lázcoz P, et al. Promoter methylation of RASSF1A associates to adult secondary glioblastomas and pediatric glioblastomas. ISRN Neurol. 2012;2012:576578. doi: 10.5402/2012/576578
27. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.
28. Purkait S, Jha P, Sharma MC, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology. 2013;33(4):405-412.
29. Suri V, Jha P, Agarwal S, et al. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol. 2011;13(10):1099-1106.
30. Uhlmann K, Rohde K, Zeller C, et al. Distinct methylation profiles of glioma subtypes. Int J Cancer. 2003;106(1):52-59.
31. Stone AR, Bobo W, Brat DJ, et al. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol. 2004;165(4):1151-1161.
32. Kim TY, Zhong S, Fields CR, et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006;66(15):7490-7501.
33. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol. 2007;82(2):133-139.
34. Tepel M, Roerig P, Wolter M, et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123(9):2080-2086.
35. Martinez R, Martin-Subero JI, Rohde V, et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics. 2009;4(4):255-264.
36. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009;19(3):188-197.
37. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48(4):403-407.
38. Srivastava A, Jain A, Jha P, et al. MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst. 2010;26(11):1613-1618.
39. Lee JY, Park CK, Park SH, et al. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst. 2011;27(11):1877-1883.
40. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345-4349.
41. Eichenmuller M, Kreuder M, Regel I, et al. Evaluating RASSF1 promoter methylation and the 16-gene signature as a prognostic marker in hepatoblastoma [abstract 63]. J Clin Oncol. 2012;30(suppl 63).
42. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315-319.
43. Wang F, Yuan S, Chen G, et al. Potential role of reactive oxygen species in mediating glioblastoma stem cell differentiation [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL. 2012 Mar. 31-Apr. 4 Philadelphia (PA): AACR. Cancer Res. 2012;72(Suppl 8).
44. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
45. Yan H, Bigner DD, Velculescu V, et al. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69(24):9157-9159.
46. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010;99(2):209-215.
47. Etcheverry A, Aubry M, De Tayrac M, et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 2010;11:701. doi:10.1186/1471-2164-11-701.